OBJECTIVES: The present study aimed at describing the implementation process of a national registry in a developing country (Brazil) and at reporting the main preliminary results of the BiobadaBrasil registry. MATERIAL AND METHODS: Through a PANLAR agreement, the Biobadaser protocol was used as a model for implementing the new registry in our country. During the first two years of this effort, the original protocol was adapted, translated, and presented to all Brazilian rheumatologists. For ten months, data of 1,037 patients (750 subjects treated with biological drugs and 287 control subjects) from 15 centers were collected. RESULTS: Most patients had rheumatoid arthritis (RA) (n = 723). Infliximab was the most frequently used anti-TNF agent, and the total exposure to biologic drugs was 2,101 patient-years. The most common reason for interrupting drug use was lack or loss of efficacy (50%), while 30% withdrew from the treatment arm due to adverse events. Three cases of tuberculosis were observed in the biologic group, with an incidence higher than that of the general Brazilian population. Infections were observed in 23% of the biologic group, and the upper respiratory tract was the most commonly affected site. Only one case of tuberculoid leprosy was observed. No deaths or malignancies attributed to drug effects were observed as of February 2010. CONCLUSIONS: The implementation of the BiobadaBrasil registry was successful, and, although recent, the registry has provided important data.
OBJECTIVES: The present study aimed at describing the implementation process of a national registry in a developing country (Brazil) and at reporting the main preliminary results of the BiobadaBrasil registry. MATERIAL AND METHODS: Through a PANLAR agreement, the Biobadaser protocol was used as a model for implementing the new registry in our country. During the first two years of this effort, the original protocol was adapted, translated, and presented to all Brazilian rheumatologists. For ten months, data of 1,037 patients (750 subjects treated with biological drugs and 287 control subjects) from 15 centers were collected. RESULTS: Most patients had rheumatoid arthritis (RA) (n = 723). Infliximab was the most frequently used anti-TNF agent, and the total exposure to biologic drugs was 2,101 patient-years. The most common reason for interrupting drug use was lack or loss of efficacy (50%), while 30% withdrew from the treatment arm due to adverse events. Three cases of tuberculosis were observed in the biologic group, with an incidence higher than that of the general Brazilian population. Infections were observed in 23% of the biologic group, and the upper respiratory tract was the most commonly affected site. Only one case of tuberculoid leprosy was observed. No deaths or malignancies attributed to drug effects were observed as of February 2010. CONCLUSIONS: The implementation of the BiobadaBrasil registry was successful, and, although recent, the registry has provided important data.
Authors: Marina Amaral de Ávila de Machado; Alessandra Maciel Almeida; Adriana Maria Kakehasi; Francisco de Assis Acurcio Journal: Rheumatol Ther Date: 2016-01-29
Authors: Roberto Ranza; Maria Celina de la Vega; Ieda Maria Magalhães Laurindo; Marìa Gimena Gómez; David Cezar Titton; Adriana Maria Kakehasi; Alejandro Brigante; Alejandro Benitez; Aline Ranzolin; Amelia Granel; Ana María Cappuccio; Ana Quinteros; André Luiz Shinji Hayata; Andrea Smichowski; Ângela Luzia Branco P Duarte; Barbara Stadler Kahlow; Carolina Sánchez Andia; Claiton Viegas Brenol; Edson Velozo; Eduardo Mussano; Enrique R Soriano; Georges Basile Christopoulos; Geraldo da Rocha Castelar Pinheiro; Gláucio Ricardo Werner de Castro; Gustavo Casado; Hellen Mary da Silveira Carvalho; Ida Elena Exeni; Inês Guimarães da Silveira; Ingrid Petkovic; Ivanio Alves Pereira; Izaias Pereira da Costa; Javier Eduardo Rosa; José Roberto Silva Miranda; Julio Cesar Bertacini de Moraes; Manoel Barros Bertolo; Manuel Buhl; Maria Alícia Lázaro; Maria de Fátima Lobato C da Sauma; Marcelo de Medeiros Pinheiro; Monica Díaz; Mônica Valéria Siqueira Santana de Vechi; Osvaldo Luis Cerda; Pablo Astesana; Pablo Finucci Curi; Paulo Louzada-Jr; Reginaldo Botelho Teodoro; Roberto Acayaba Toledo; Sílvia Papasidero; Valeria Valim; Vander Fernandes; Veronica Saurit; Washington Alves Bianchi; Rogério de Melo Costa Pinto; Miguel Angel Descalzo; Juan Jesus Gomez-Reino Journal: Clin Rheumatol Date: 2019-04-17 Impact factor: 2.980
Authors: Anna L Cogen; Eglantine Lebas; Barbara De Barros; James P Harnisch; William R Faber; Diana N Lockwood; Stephen L Walker Journal: Am J Trop Med Hyg Date: 2020-05 Impact factor: 2.345
Authors: Maria de la Vega; Hellen M da Silveira de Carvalho; Lucio Ventura Ríos; Maria V Goycochea Robles; Gustavo C Casado Journal: Rheumatol Int Date: 2012-12-23 Impact factor: 2.631
Authors: Carina Mori Frade Gomes; Maria Teresa Terreri; Maria Isabel de Moraes-Pinto; Cássia Barbosa; Natália Pereira Machado; Maria Roberta Melo; Marcelo Medeiros Pinheiro Journal: Mem Inst Oswaldo Cruz Date: 2015-11 Impact factor: 2.743
Authors: Marina Amaral de Ávila Machado; Cristiano Soares de Moura; Felipe Ferré; Sasha Bernatsky; Elham Rahme; Francisco de Assis Acurcio Journal: Rev Saude Publica Date: 2016-08-22 Impact factor: 2.106
Authors: Andrea B V Lomonte; Sebastião C Radominski; Flora M D Marcolino; Claiton V Brenol; Cristiano A F Zerbini; Erika G García; Ermeg L Akylbekova; Ricardo Rojo; Dario Ponce de Leon Journal: Medicine (Baltimore) Date: 2018-08 Impact factor: 1.817